Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Cellular therapies for NHL: current challenges and perspectives

Ian Flinn • 1 Dec 2018
ASH 2018
B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma CAR-T
PRISM

Speaking the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition, held in San Diego, CA, Ian Flinn, MD, PhD, of the Tennessee Oncology, Nashville, TN, discusses his perspective on the promise and challenges of cellular therapy. Dr Flinn highlights the need to continue investigating other immunotherapy and small molecular options, rather than focusing solely on one therapy type.

More from Ian Flinn

2:18
SGN35-027: Brentuximab vedotin with nivolumab, doxorubicin, and dacarbazine in HL
Ian Flinn • 9 Dec 2021
0:57
Unanswered questions in frontline CLL treatment
Ian Flinn • 9 Dec 2021
1:55
Umbralisib and ublituximab in patients with CLL and comorbidities
Ian Flinn • 9 Dec 2021
2:48
Debulking strategies in CLL before venetoclax therapy
Ian Flinn • 9 Dec 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals